{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:57:52Z","timestamp":1775332672960,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["RD24\/0004\/0018"],"award-info":[{"award-number":["RD24\/0004\/0018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus often leads to cardiovascular and renal complications, particularly in patients with lupus nephritis. In clinical practice, renal treatment response is commonly assessed using the Complete Renal Response criteria defined by the Consensus document of the Spanish Group for the Study of the Glomerular Diseases. These criteria, however, rely predominantly on proteinuria while albuminuria is often overlooked. The primary objective of our study was to assess the prevalence of pathological albuminuria in patients who met Complete Renal Response criteria. Secondary objectives included evaluating whether residual albuminuria identifies patients with different clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-centre, ambispective, observational study included 91 LN patients. Pathological albuminuria was defined as urinary albumin-creatinine ratio &amp;gt; 30 mg\/g. Outcomes were compared between patients with and without pathological albuminuria despite achieving Complete Renal Response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients who met Complete Renal Response criteria, 80.5% had pathological albuminuria at the time of remission, and 55.8% continued to show it at the end of follow-up. Notably, patients with pathological albuminuria at the time of remission had significantly higher proteinuria levels both at disease onset and remission. Furthermore, persistent pathological albuminuria at follow-up was associated with more intensive antiproteinuric treatment. This therapeutic approach led to a significant reduction in both proteinuria and albuminuria titers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pathological albuminuria remains common in lupus nephritis patients who meet Complete Renal Response criteria. Although cardiovascular events were infrequent during follow-up, the presence of persistent pathological albuminuria in patients meeting Complete Renal Response criteria underscores the need for close monitoring and therapeutic optimization, given its well-established association with adverse renal and cardiovascular outcomes in other glomerular diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag032","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:49:45Z","timestamp":1773330585000},"source":"Crossref","is-referenced-by-count":0,"title":["Albuminuria in Lupus Nephritis: the hidden threat to cardiovascular health"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2206-5480","authenticated-orcid":false,"given":"Julio Francisco","family":"Colina-Garc\u00eda","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hospital Universitario 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Martin Cap\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Galindo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario 12 de Octubre , Madrid,","place":["Spain"]},{"name":"Department of Medicine, Research Institute of Hospital Universitario 12 de Octubre (imas12) , Madrid,","place":["Spain"]},{"name":"Department of Medicine, Complutense University of Madrid , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-6973","authenticated-orcid":false,"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario 12 de Octubre , Madrid,","place":["Spain"]},{"name":"Department of Medicine, Research Institute of Hospital Universitario 12 de Octubre (imas12) , Madrid,","place":["Spain"]},{"name":"Department of Medicine, Complutense University of Madrid , Madrid,","place":["Spain"]},{"name":"RICORS2040-Renal, ISCIII , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026040415215034200_rkag032-B1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.ki.5002118","article-title":"The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years","volume":"71","author":"Markowitz","year":"2007","journal-title":"Kidney Int"},{"key":"2026040415215034200_rkag032-B2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nefro.2022.10.005","article-title":"Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis","volume":"43","author":"Rojas-Rivera","year":"2023","journal-title":"Nefrolog\u00eda"},{"key":"2026040415215034200_rkag032-B3","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026040415215034200_rkag032-B4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","article-title":"Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity","volume":"78","author":"Jesus","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026040415215034200_rkag032-B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hfc.2005.11.004","article-title":"Albuminuria and cardiovascular risk","volume":"2","author":"Bogojevic","year":"2006","journal-title":"Heart Failure Clinics"},{"key":"2026040415215034200_rkag032-B6","first-page":"f324","article-title":"Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis","volume":"346","author":"Nitsch","year":"2013","journal-title":"BMJ (Online)"},{"key":"2026040415215034200_rkag032-B7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"2026040415215034200_rkag032-B8","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"2026040415215034200_rkag032-B9","doi-asserted-by":"crossref","first-page":"e030131","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026040415215034200_rkag032-B10","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group","year":"2024"},{"key":"2026040415215034200_rkag032-B11","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology (United Kingdom)"},{"key":"2026040415215034200_rkag032-B12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nefro.2024.07.005","article-title":"Lupus nephritis: 10 questions to think about","volume":"45","author":"Morales","year":"2025","journal-title":"Nefrologia"},{"key":"2026040415215034200_rkag032-B13","first-page":"151","author":"Rojas-Rivera"},{"key":"2026040415215034200_rkag032-B14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten antiproteinuric properties of diuretics","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026040415215034200_rkag032-B15","doi-asserted-by":"crossref","first-page":"sfae237","DOI":"10.1093\/ckj\/sfae237","article-title":"Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a CKJ controversy","volume":"17","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026040415215034200_rkag032-B16","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026040415215034200_rkag032-B17","doi-asserted-by":"crossref","first-page":"1105676","DOI":"10.3389\/fneph.2023.1105676","article-title":"Lupus nephropathy beyond immunosuppression: searching for nephro and cardioprotection","volume":"3","author":"Morales","year":"2023","journal-title":"Front Nephrol"},{"key":"2026040415215034200_rkag032-B18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/annrheumdis-2022-222512","article-title":"SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection","volume":"81","author":"Morales","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026040415215034200_rkag032-B19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","article-title":"Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study","volume":"112","author":"Zen","year":"2023","journal-title":"Eur J Intern Med"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag032\/67373516\/rkag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag032\/67373516\/rkag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag032\/67373516\/rkag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:21:58Z","timestamp":1775330518000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag032\/8525345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag032","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag032"}}